68 completed, 28 active not recruiting, 17 terminated, 13 withdrawn. 77 Phase 2, 54 Phase 1, 13 Phase 3, 8 Not applicable, 5 Early Phase 1.
Follow Recurrent Ovarian Carcinoma: new trials by email Literature Review of Recurrent Ovarian Carcinoma trials Research Report on Recurrent Ovarian Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy Biospecimen Collection, Placebo Administration, Probiotic - Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma | Early Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 161 | 2026-03-06 | 2026-08-17 |
| An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study Behavioral Intervention, Best Practice, Biospecimen Collection - Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Not applicable | Recruiting | Roswell Park Cancer Institute | 120 | 2025-06-04 | 2026-01-06 |
| Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer Biopsy, Biospecimen Collection, Niraparib - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2025-04-18 | 2025-05-23 | |
| Helping Ovarian Cancer Patients Cope With Their Illness (HOPE) Behavioral Intervention, Electronic Health Record Review, Interview - Recurrent Ovarian Carcinoma | Not applicable | Suspended | Fred Hutchinson Cancer Center | 60 | 2025-02-24 | 2026-07-22 |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
| A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results Magnetic resonance imaging as fpr clinical practice - Ovarian Cancer, Recurrent Ovarian Carcinoma | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 220 | 2024-09-01 | 2024-08-07 | |
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study Non-Interventional Study - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Recruiting | University of Washington | 2000 | 2024-01-02 | 2026-04-17 | |
| Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors Dalpiciclib plus letrozole - Recurrent Ovarian Carcinoma | Phase 2 | Unknown | Fengzhi Feng | 30 | 2023-11-17 | 2024-02-06 |
| Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Carboplatin or cisplatin, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, Bevacizumab or biosimilar - Recurrent Ovarian Carcinoma | Not applicable | Recruiting | The University of Hong Kong | 18 | 2023-11-01 | 2025-06-11 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 165 | 2023-04-25 | 2026-10-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-11-02 |
| Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation Bevacizumab, Niraparib - Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Terminated | University of Oklahoma | 9 | 2023-02-15 | 2026-06-03 |
| Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer Lenvatinib+Toripalimab. - Recurrent Ovarian Carcinoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 69 | 2023-02-01 | 2024-02-05 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer Albumin-bound paclitaxel and bevacizumab - Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 2 | Unknown | Lei Li | 50 | 2022-03-27 | 2022-04-04 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Lenvatinib, Paclitaxel, Pembrolizumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | Floor Backes, MD | 38 | 2021-09-01 | 2026-10-21 |
Showing 20 of 150. Sign in to see all of them.
Ovarian Neoplasms (150) · Fallopian Tube Neoplasms (104) · Breast Neoplasms (18) · Endometrial Neoplasms (13) · Brenner Tumor (10) · Uterine Cervical Neoplasms (9) · Prostatic Neoplasms (8) · Triple Negative Breast Neoplasms (7) · Carcinoma, Renal Cell (6) · Neoplasm Metastasis (6) · Pancreatic Neoplasms (6) · Lung Neoplasms (5) · Melanoma (5) · Stomach Neoplasms (5) · Carcinoma, Hepatocellular (4)
Adnexal Diseases (150) · Endocrine Gland Neoplasms (150) · Endocrine System Diseases (150) · Female Urogenital Diseases (150) · Female Urogenital Diseases and Pregnancy Complications (150) · Genital Diseases (150) · Genital Diseases, Female (150) · Genital Neoplasms, Female (150) · Gonadal Disorders (150) · Neoplasms by Site (150) · Ovarian Diseases (150) · Urogenital Diseases (150) · Urogenital Neoplasms (150) · Neoplasms (146) · Fallopian Tube Diseases (104)
Bevacizumab (23) · Paclitaxel (23) · Disulfides (21) · Immunoglobulin G (21) · Taxes (20) · Carboplatin (18) · Specimen Handling (16) · Magnetic Resonance Spectroscopy (15) · Gemcitabine (13) · Doxorubicin (12) · liposomal doxorubicin (12) · pembrolizumab (11) · Cyclophosphamide (9) · olaparib (9) · Biopsy (8)
National Cancer Institute (NCI) (44) · Gynecologic Oncology Group (16) · M.D. Anderson Cancer Center (12) · Mayo Clinic (12) · Roswell Park Cancer Institute (10) · City of Hope Medical Center (3) · GOG Foundation (3) · Jonsson Comprehensive Cancer Center (3) · University of Washington (3) · AGO Research GmbH (2) · Albert Einstein College of Medicine (2) · Barbara Ann Karmanos Cancer Institute (2) · Northwestern University (2) · Ohio State University Comprehensive Cancer Center (2) · University of Utah (2)
United States (124) · Canada (9) · Puerto Rico (6) · South Korea (6) · China (5) · Germany (4) · Italy (3) · Japan (3) · Austria (2) · Belgium (2) · France (2) · Spain (2) · Denmark (1) · Egypt (1) · Estonia (1)
Emese Zsiros (6) · Amir A Jazaeri (5) · Kunle Odunsi (3) · Shannon N Westin (3) · Amit Oza (2) · Andrea E Wahner Hendrickson (2) · Bradley J Monk (2) · Emese Zsiros, MD (2) · Floor Backes, MD (2) · Gerardo Colon-Otero (2) · Lilie L Lin (2) · Matthew S. Block, M.D., Ph.D. (2) · Robert Coleman (2) · A P Chen (1)
PMID 37185961, PMID 32379297, PMID 25318437, PMID 25488966, PMID 26554651, PMID 26586415, PMID 27217446, PMID 28341300, PMID 28438473, PMID 29242937, PMID 29921512, PMID 30309721, PMID 30587441, PMID 31722153, PMID 32463741, PMID 32553118, PMID 32606097, PMID 33048619, PMID 33109627, PMID 33211063, PMID 33318079, PMID 33485453, PMID 34132071, PMID 34155084, PMID 34408750, PMID 34531249, PMID 35007153, PMID 35130043, PMID 35133871, PMID 35138919, PMID 35170751, PMID 35254001, PMID 35290101, PMID 35357903, PMID 35671108, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37702588, PMID 37934000, PMID 38009662, PMID 38471508, PMID 38591867, PMID 38635934, PMID 39208372, PMID 39292975, PMID 39361946, PMID 39379328, PMID 39638782, PMID 39666929
U10CA027469 (27), U10CA180868 (27), P30CA015083 (5), N01CM00032 (4), P30CA016056 (4), UM1CA186709 (4), N01CM00038 (3), N01CM00071 (3), N01CM62203 (3), P30CA006516 (3), P30CA013330 (3), P50CA136393 (3), U10CA101165 (3), U10CA180820 (3), N01CM00099 (2)